Dr. Weiss is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
195 Little Albany St Ste 2701
New Brunswick, NJ 08901Phone+1 732-235-2465Fax+1 732-235-8808
Summary
- Melanoma, immunotherapy, merkel cell carcinoma, cutaneous squamous cell carcinoma, basal cell carcinoma
Education & Training
New York University School of MedicinePost-Doctoral Fellowship, 2015 - 2016- NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 2012 - 2015
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 2009 - 2012
Albert Einstein College of MedicineClass of 2009
Certifications & Licensure
NJ State Medical License 2021 - 2025
CT State Medical License 2016 - 2022
NY State Medical License 2011 - 2016
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma Start of enrollment: 2015 Nov 23
- A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC) Start of enrollment: 2020 Sep 14
Publications & Presentations
PubMed
- Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases.Sarah A Weiss, Dijana Djureinovic, Wei Wei, Thuy Tran, Matthew Austin
Journal of Clinical Oncology. 2025-03-06 - 1 citationsPatterns of brain metastases response to immunotherapy with pembrolizumab.Amit Mahajan, Sarah L Goldberg, Sarah A Weiss, Thuy Tran, Kanwar Singh
Journal of Neuro-Oncology. 2024-09-01 - 10 citationsA Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progres...Sarah A Weiss, Mario Sznol, Montaser Shaheen, Miguel-Ángel Berciano-Guerrero, Eva Muñoz Couselo
Clinical Cancer Research. 2024-01-05
Press Mentions
How Common Is Skin Cancer? And More Questions You’re Afraid to AskMay 2nd, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
